A phase II study of axitinib in advanced neuroendocrine tumors

Neuroendocrine tumors (NETs) are highly vascular neoplasms overexpressing vascular endothelial growth factor (VEGF) as well as VEGF receptors (VEGFR). Axitinib is a potent, selective inhibitor of VEGFR-1, -2 and -3, currently approved for the treatment of advanced renal cell carcinoma. We performed...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Endocr Relat Cancer
Main Authors: Strosberg, J R, Cives, M, Hwang, J, Weber, T, Nickerson, M, Atreya, C E, Venook, A, Kelley, R K, Valone, T, Morse, B, Coppola, D, Bergsland, E K
Format: Artigo
Sprog:Inglês
Udgivet: 2016
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963225/
https://ncbi.nlm.nih.gov/pubmed/27080472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-16-0008
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker